Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 HKD | -0.57% | +0.19% | -21.69% |
05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.69% | 629M | |
+26.31% | 44.96B | |
-0.61% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.49% | 26.08B | |
-21.48% | 19.03B | |
+6.29% | 12.75B | |
+27.59% | 12.06B | |
-3.45% | 11.75B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Logs Upbeat Results From Anti-Tumor Drug's Australian Trials